Therapeutic effectiveness of biosimilar standard interferon versus pegylated interferon for chronic hepatitis C genotypes 2 or 3

Vigani, Aline Gonzalez; Gonçales, Eduardo Sellan; Postal Pavan, Maria Helena; Genari, Flavia; Tozzo, Raquel; Kroll Lazarini, Maria Silvia; Fais, Viviane; Feltrin, Adriana; Gonçales, Neiva Sellan; Gonçales, Fernando Lopes

doi:10.1016/S1413-8670(12)70316-1

The Brazilian Journal of Infectious Diseases

ISSN: 1413-8670

The Brazilian Journal of Infectious Diseases is the official publication of the Brazilian Society of Infectious Diseases (SBI). It aims to publish relevant articles in the broadest sense on all aspects of microbiology, infectious diseases and immune response to infectious agents.
The BJID is a bimonthly publication and one of the most influential journals in its field in Brazil and Latin America with a high impact factor. Since its inception it has garnered a growing share of the publishing market.

Indexed in:

CABI Publishing; Chemical Abstracts (CAS); China Education Publications Import and Export Corporation (CEPIEC); EBSCO Database (Premium Research); Elsevier Science - Bibliographic Databases Division; Embase/Excerpta Medica; Gale Cengage Learning; Index Copernicus International; ISI (Web of Science) - Science Citation Index Expanded (SCISEARCH); Journal Citation Reports (Science Edition); Kessler-Hancok Information Service; Latin America and Caribean Literature of Health Science (LILACS); LATINDEX; Medline/ Index Medicus/Pubmed; Qualis International (CAPES): B3 (International Quality); Redalyc (Network of Scientific Journals of Latin America, Caribbean, Spain and Portugal) SCIELO; SCIRUS (Elsevier); SCOPUS Index; Sociedad Iberoamericana de Información Cientifica (SIIC); Subis Database (SUBIS Bulletin); Swets Blackwell; Teldan Database Production; The US Library of Congress Office; Ulrich¿s Periodicals Directory.

From January 2005 to December 2010, 172 patients with a mean age of 44 +/− 9.3 years were included. There were eight (4.7%) patients with HCV genotype 2 infections. One hundred fourteen (66.3%) were treated with biosimilar standard IFN plus RBV, whist 58 (33.7%) patients were treated with Peg-IFN plus RBV. Between the two groups, there were no significant differences regarding age, gender, glucose level, platelet count, hepatic necroinflammatory grade, and hepatic fibrosis stage. Overall, 59.3% (102/172) patients had SVR. In patients treated with Peg-IFN plus RBV, 79.3% (46/58) had SVR compared to 49.1% (56/114) among those treated with biosimilar standard IFN plus RBV (p=0.0001).

Conclusion

In patients with HCV genotypes 2 or 3 infection, a higher SVR was observed in patients receiving Peg-IFN plus RBV related to patients treated with biosimilar standard IFN plus RBV.

Keywords:

Interferons

Hepatitis C

Treatment outcome

Full text is only aviable in PDF

References

[1.]

W.R. Kim, R.S. Brown Jr., N.A. Terrault, H. El-Serag.

Burden of liver disease in the United States: summary of a workshop.

Hepatology, 36 (2002), pp. 227-242

http://dx.doi.org/10.1053/jhep.2002.34734 | Medline

[2.]

W.C. Grant, R.R. Jhaveri, J.G. McHutchison, K.A. Schulman, T.L. Kauf.

Trends in health care resource use for hepatitis C virus infection in the United States.

Hepatology, 42 (2005), pp. 1406-1413

http://dx.doi.org/10.1002/hep.20941 | Medline

[3.]

E.J. Bini, S. Mehandru.

Sustained virological response rates and health-related quality of life after interferon and ribavirin therapy in patients with chronic hepatitis C virus infection and persistently normal alanine aminotransferase levels.

Aliment Pharmacol Ther, 23 (2006), pp. 777-785

http://dx.doi.org/10.1111/j.1365-2036.2006.02819.x | Medline

[4.]

T. Poynard, J. McHutchison, M. Manns, et al.

Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

Gastroenterology, 122 (2002), pp. 1303-1313

Medline

[5.]

M.P. Manns, J.G. McHutchison, S.C. Gordon, et al.

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Lancet, 358 (2001), pp. 958-965

Medline

[6.]

M.W. Fried, M.L. Shiffman, K.R. Reddy, et al.

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

N Engl J Med, 347 (2002), pp. 975-982

http://dx.doi.org/10.1056/NEJMoa020047 | Medline

[7.]

Ministério da Saúde (Brasil).

Portaria 639. Anexo I: Protocolo clínico e diretrizes terapêuticas da hepatite viral crônica tipo C.

Diário Oficial da União, DF, (2000), pp. 34

[8.]

Clinical guidelines for hepatitis C 2007, Dispõe sobre o Protocolo Clínico e Diretrizes Terapêuticas para Hepatite Viral C. 2007. Report N°: Portaria N° 34, de 28 de setembro de 2007; ID6065503-0. Brasil: Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de DST AeHVPN.

[9.]

P. Bedossa, T. Poynard, The METAVIR cooperative study group.

An algorithm for the grading of activity in chronic hepatitis C.

Hepatology, 24 (1996), pp. 289-293

http://dx.doi.org/10.1002/hep.510240201 | Medline

[10.]

D. Ge, J. Fellay, A.J. Thompson, et al.

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.

Nature, 461 (2009), pp. 399-401

http://dx.doi.org/10.1038/nature08309 | Medline

[11.]

G.L. Davis, J.B. Wong, J.G. McHutchison, M.P. Manns, J. Harvey, J. Albrecht.

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

Hepatology, 38 (2003), pp. 645-652

http://dx.doi.org/10.1053/jhep.2003.50364 | Medline

[12.]

I.M. Jacobson, R.S. Brown Jr., B. Freilich, et al.

Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial.

Hepatology, 46 (2007), pp. 971-981

http://dx.doi.org/10.1002/hep.21932 | Medline

[13.]

N. Khokhar.

Effectiveness of 48 weeks interferon alfa-2b in combination with ribavirin as initial treatment of chronic hepatitis.

J Ayub Med Coll Abbottabad, 14 (2002), pp. 5-8

Medline

[14.]

M.G. Rumi, A. Aghemo, R. D’Ambrosio, et al.

Lack of rapid virological response predicts interferon-alpha2b/ribavirin therapy failure in HCV genotype 2 patients: a single-centre study.

Antivir Ther, 12 (2007), pp. 1033-1040

Medline

[15.]

R.N. Acras, M.L. Pedroso, L.C. Caum, J.C. Pisani, H.M. Amarante, E.R. Carmes.

The sustained response rates for chronic hepatitis C patients undergoing therapy with the several interferons and ribavarins supplied by Brazilians Health Ministry is comparable to those reported in the literature.

Arq Gastroenterol, 41 (2004), pp. 3-9

http://dx.doi.org//S0004-28032004000100002 | Medline

[16.]

A.V. Alves, A.P. de Azevedo, C. Perin, et al.

Interferon-alpha and ribavirin therapy on chronic hepatitis C virus infection: the experience of Rio Grande do Sul State Health Department, Brazil.

Arq Gastroenterol, 40 (2003), pp. 227-232

http://dx.doi.org//S0004-28032003000400006 | Medline

[17.]

E.R. Parise, A.C. de Oliveira, R.D. Conceição, A.C. Amaral, K. Leite.

Response to treatment with interferon-alpha and ribavirin in patients with chronic hepatitis C virus genotypes 2 and 3 depends on the degree of hepatic fibrosis.

Braz J Infect Dis, 10 (2006), pp. 78-81

Medline

[18.]

F.L. Gonçales Jr., A. Vigani, N. Gonçales, et al.

Weight-based combination therapy with peginterferon alpha-2b and ribavirin for naïve, relapser and non-responder patients with chronic hepatitis C.

Braz J Infect Dis, 10 (2006), pp. 311-316

Medline

Indexed in:

Follow us:

Subscribe to our newsletter